UNCY - Unicycive Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

Unicycive Therapeutics, Inc.

4300 El Camino Real
Suite 210
Los Altos, CA 94022
United States
(650) 351-4495

Full Time Employees12

Key Executives

NameTitlePayExercisedYear Born
Dr. Shalabh K. Gupta M.D., MPAFounder, Chairman, CEO & Pres1.46MN/A1974
Dr. Pramod Gupta Ph.D.Exec. VP of Pharmaceutical & Bus. Operations779.18kN/A1960
Mr. Douglas Jermasek M.B.A.Exec. VP of Corp. Strategy430.81kN/A1961
Mr. John W. Townsend CPAChief Financial OfficerN/AN/A1962
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Corporate Governance

Unicycive Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.